Introduction: Peritoneal carcinomatosis presents significant treatment challenges. Cytoreductive surgery (CRS) with hyperthermic intraperitoneal chemotherapy (HIPEC) offers a promising therapeutic approach. Patient selection remains critical, and the role of age as an exclusion criterion requires further investigation. This study evaluates whether age influences postoperative outcomes in CRS-HIPEC patients. Methods: A retrospective review of a prospective comprehensive database of 271 CRS-HIPEC procedures performed between 2018 and 2023 was conducted. Logistic regression assessed the relationship between age and postoperative outcomes. Age groups (18–44, 45–69, ≥70 years) were compared based on demographic data, primary tumor site, Peritoneal Cancer Index scores, and key outcome measures. Results: Across the different age groups, there were no significant differences in PCI scores, recurrence, disease-free survival, 30-day morbidity, or mortality. Length of stay was longer in older patients (p= 0.009). Patients aged ≥70 had higher readmission rates (p= 0.041) and were more often discharged to transitional care facilities (p= 0.001). Older patients were also more likely to experience Clavien–Dindo grade III or higher complications (p= 0.008). Logistic regression confirmed these findings. Continuous age analysis yielded similar results and revealed significant differences in race and primary organ involvement. Conclusions: Age is not a significant predictor of 30-day morbidity, mortality, or survival outcomes in patients undergoing CRS-HIPEC. However, older patients require closer attention to discharge planning and readmission risk management. This study highlights the importance of comprehensive patient assessment beyond age and underscores the need for further research to better understand factors influencing outcomes in this population.
引言：腹膜癌病治疗面临重大挑战。细胞减灭术联合腹腔热灌注化疗是一种前景广阔的治疗方法。患者选择仍至关重要，年龄作为排除标准的作用需进一步探讨。本研究评估年龄是否影响接受CRS-HIPEC治疗患者的术后结局。 方法：对2018年至2023年间271例CRS-HIPEC手术的前瞻性综合数据库进行回顾性分析。采用逻辑回归评估年龄与术后结局的关系。根据人口统计学数据、原发肿瘤部位、腹膜癌指数评分及关键结局指标，比较不同年龄组（18-44岁、45-69岁、≥70岁）的差异。 结果：各年龄组在PCI评分、复发率、无病生存期、30天并发症发生率及死亡率方面均无显著差异。老年患者住院时间更长（p=0.009）。≥70岁患者再入院率更高（p=0.041），且更常转至过渡护理机构（p=0.001）。老年患者发生Clavien-Dindo III级或以上并发症的风险也更高（p=0.008）。逻辑回归分析证实了这些发现。连续年龄分析得出相似结果，并显示种族和原发器官受累存在显著差异。 结论：年龄并非预测CRS-HIPEC患者30天并发症、死亡率或生存结局的显著因素。然而，老年患者需要更密切地关注出院规划和再入院风险管理。本研究强调超越年龄因素进行综合患者评估的重要性，并指出需进一步研究以更好理解影响该人群结局的因素。
肿瘤(癌症)患者之家